Second-line treatment of ovarian carcinoma with pegylated liposomal doxorubicin (Caelyx®)


Year:

Session type:

Richard Turkington, Paula Scullin, Joanne Millar

Northern Ireland Cancer Centre, Belfast, Northern Ireland, UK

Abstract

Background

Over 80% of patients with advanced ovarian carcinoma achieve responses to initial platinum- and paclitaxel-based treatment but will ultimately relapse and develop drug-resistant disease. Patients with progression on or within 6 months of primary therapy are considered paltinum-resistant while those who progress within 6 to 12 months are termed potentially platinum-sensitive. Both groups may be treated with Pegylated Liposomal Doxorubicin (Caelyx®) as second line chemotherapy but response rates and survival are poor. We sought to determine the efficacy of Caelyx® for these patient populations in our practice.

Method

Patients with relapsed ovarian carcinoma received Pegylated Liposomal Doxorubicin (Caelyx®) 50mg/m2 every 28 days and were stratified as either platinum-resistant or potentially platinum-sensitive. In this retrospective analysis response rates, progression-free and overall survival for our patient populations were compared with published data.

Results

A total of 52 patients were treated between 2003-2007 of which 39 were platinum-resistant and 13 potentially platinum-sensitive. The median age was 60 (range 37-74). The overall response rate was 7.7% compared to the published rate of 19.7% and for the resistant patients 7.4% compared with 12.3%. Median overall survival times for all and platinum-resistant patients were 31 and 29 weeks respectively, compared with 60 and 35.6 weeks. Progression-free survival for all and platinum-resistant patients were 11.3 and 10.9 respectively compared with 16.1 and 9.1 weeks.

Conclusion

Second-line treatment of platinum-resistant and potentially platinum-sensitive patients with Pegylated Liposomal Doxorubicin (Caelyx®) results in poor response rates and overall survival. Prognosis remains poor in this particularly challenging group of patients.

Background

Over 80% of patients with advanced ovarian carcinoma achieve responses to initial platinum- and paclitaxel-based treatment but will ultimately relapse and develop drug-resistant disease. Patients with progression on or within 6 months of primary therapy are considered paltinum-resistant while those who progress within 6 to 12 months are termed potentially platinum-sensitive. Both groups may be treated with Pegylated Liposomal Doxorubicin (Caelyx®) as second line chemotherapy but response rates and survival are poor. We sought to determine the efficacy of Caelyx® for these patient populations in our practice.

Method

Patients with relapsed ovarian carcinoma received Pegylated Liposomal Doxorubicin (Caelyx®) 50mg/m2 every 28 days and were stratified as either platinum-resistant or potentially platinum-sensitive. In this retrospective analysis response rates, progression-free and overall survival for our patient populations were compared with published data.

Results

A total of 52 patients were treated between 2003-2007 of which 39 were platinum-resistant and 13 potentially platinum-sensitive. The median age was 60 (range 37-74). The overall response rate was 7.7% compared to the published rate of 19.7% and for the resistant patients 7.4% compared with 12.3%. Median overall survival times for all and platinum-resistant patients were 31 and 29 weeks respectively, compared with 60 and 35.6 weeks. Progression-free survival for all and platinum-resistant patients were 11.3 and 10.9 respectively compared with 16.1 and 9.1 weeks.

Conclusion

Second-line treatment of platinum-resistant and potentially platinum-sensitive patients with Pegylated Liposomal Doxorubicin (Caelyx®) results in poor response rates and overall survival. Prognosis remains poor in this particularly challenging group of patients.

Share this abstractTweet about this on TwitterPrint this pageShare on FacebookEmail this to someoneShare on LinkedIn